NO319829B1 - Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet - Google Patents

Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet Download PDF

Info

Publication number
NO319829B1
NO319829B1 NO19975492A NO975492A NO319829B1 NO 319829 B1 NO319829 B1 NO 319829B1 NO 19975492 A NO19975492 A NO 19975492A NO 975492 A NO975492 A NO 975492A NO 319829 B1 NO319829 B1 NO 319829B1
Authority
NO
Norway
Prior art keywords
cortisol
dexamethasone
dose
agonist
use according
Prior art date
Application number
NO19975492A
Other languages
English (en)
Norwegian (no)
Other versions
NO975492D0 (no
NO975492L (no
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Publication of NO975492D0 publication Critical patent/NO975492D0/no
Publication of NO975492L publication Critical patent/NO975492L/no
Publication of NO319829B1 publication Critical patent/NO319829B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19975492A 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet NO319829B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
PCT/SE1996/000708 WO1996038179A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome

Publications (3)

Publication Number Publication Date
NO975492D0 NO975492D0 (no) 1997-11-28
NO975492L NO975492L (no) 1998-01-27
NO319829B1 true NO319829B1 (no) 2005-09-19

Family

ID=20398470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975492A NO319829B1 (no) 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet

Country Status (16)

Country Link
US (1) US6410339B1 (sv)
EP (1) EP0835138B1 (sv)
JP (1) JPH11505850A (sv)
CN (1) CN1078479C (sv)
AT (1) ATE235258T1 (sv)
AU (1) AU716671B2 (sv)
BR (1) BR9608683A (sv)
CA (1) CA2222215A1 (sv)
DE (1) DE69626982T2 (sv)
DK (1) DK0835138T3 (sv)
ES (1) ES2189872T3 (sv)
NO (1) NO319829B1 (sv)
PT (1) PT835138E (sv)
RU (1) RU2171471C2 (sv)
SE (1) SE505391C2 (sv)
WO (1) WO1996038179A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217505B2 (en) * 1998-02-26 2007-05-15 Cortendo Ab Method for determining whether condition is symptom of metabolic syndrome
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
RU2520080C2 (ru) * 2006-10-06 2014-06-20 Нестек С.А. Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
RU2444298C1 (ru) * 2010-07-15 2012-03-10 Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) Способ диагностики метаболического синдрома
CN105973881A (zh) * 2016-04-27 2016-09-28 樊福好 一种检测机体活度的溶液及检测方法

Also Published As

Publication number Publication date
DE69626982T2 (de) 2004-03-04
NO975492D0 (no) 1997-11-28
RU2171471C2 (ru) 2001-07-27
DE69626982D1 (de) 2003-04-30
EP0835138A1 (en) 1998-04-15
WO1996038179A1 (en) 1996-12-05
EP0835138B1 (en) 2003-03-26
AU716671B2 (en) 2000-03-02
ES2189872T3 (es) 2003-07-16
AU5917396A (en) 1996-12-18
CN1078479C (zh) 2002-01-30
ATE235258T1 (de) 2003-04-15
SE505391C2 (sv) 1997-08-18
CA2222215A1 (en) 1996-12-05
CN1185743A (zh) 1998-06-24
PT835138E (pt) 2003-08-29
JPH11505850A (ja) 1999-05-25
NO975492L (no) 1998-01-27
MX9709234A (es) 1998-10-31
US6410339B1 (en) 2002-06-25
SE9501991L (sv) 1996-12-01
DK0835138T3 (da) 2003-07-21
BR9608683A (pt) 1999-12-07
SE9501991D0 (sv) 1995-05-30

Similar Documents

Publication Publication Date Title
Li et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)
NO319829B1 (no) Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet
Ferron et al. Serum leptin concentrations in patients with anorexia nervosa, bulimia nervosa and non‐specific eating disorders correlate with the body mass index but are independent of the respective disease
Hofmann et al. Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening
Goland et al. Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses
Houdeau et al. Sex steroid regulation of macrophage migration inhibitory factor in normal and inflamed colon in the female rat
Stolk et al. Gender differences in the associations between cortisol and insulin in healthy subjects
Nieman et al. The ovine corticotropin-releasing hormone (CRH) stimulation test is superior to the human CRH stimulation test for the diagnosis of Cushing's disease
Fang et al. Activiated galanin receptor 2 attenuates insulin resistance in skeletal muscle of obese mice
Grulet et al. Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index
Armanini et al. Alzheimer’s disease: pathophysiological implications of measurement of plasma cortisol, plasma dehydroepiandrosterone sulfate, and lymphocytic corticosteroid receptors
Wodarz et al. Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression
Cleare et al. Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan
Ferrier et al. Gonadotrophin secretion abnormalities in chronic schizophrenia
Franik et al. The association between 24-hour ambulatory blood pressure measurement and selected biochemical and anthropometric parameters in women with polycystic ovary syndrome.
Sumino et al. Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women
US7217505B2 (en) Method for determining whether condition is symptom of metabolic syndrome
MXPA97009234A (en) Preparation for the diagnosis of the metabolic syndrome and diseases that include the sindr
JP4044842B2 (ja) 肥満を処置し得る薬剤のスクリーニング法
Khattak et al. Comparison of Estradiol levels in Polycystic Ovary Syndrome and non-Polycystic Ovary Syndrome Infertile Patients
Meijin et al. A3081 VDR agonist prevents diabetic endothelial dysfunction through inhibition of prolyl isomerase-1 mediated mitochondrial oxidative stress and inflammation
Hasan et al. The Effect of Body Weight Gain with or Without Diabetes Type 2 on the Levels of Noradrenalin and Some Neurotrophins
He et al. Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy
Shoaib et al. Estemation of Serum Gonadotropin Hromones and Insulin levels among Stein-Leventhal syndrome Patients
Abd Alkhalik et al. Association of soluble E-selectin and morning blood pressure surge in patients with essential hypertension